Cargando…

Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are hematological malignancies of unclear etiology where oxidative stress may contribute to the pathogenesis. Methylarginines, naturally occurring inhibitors of NO synthase, can increase superoxide generation from uncoupled NO synthase. We found significant increase i...

Descripción completa

Detalles Bibliográficos
Autores principales: Štikarová, Jana, Suttnar, Jiří, Pimková, Kristýna, Chrastinová-Mášová, Leona, Čermák, Jaroslav, Dyr, Jan E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765587/
https://www.ncbi.nlm.nih.gov/pubmed/23958336
http://dx.doi.org/10.1186/1756-8722-6-58
_version_ 1782283344879288320
author Štikarová, Jana
Suttnar, Jiří
Pimková, Kristýna
Chrastinová-Mášová, Leona
Čermák, Jaroslav
Dyr, Jan E
author_facet Štikarová, Jana
Suttnar, Jiří
Pimková, Kristýna
Chrastinová-Mášová, Leona
Čermák, Jaroslav
Dyr, Jan E
author_sort Štikarová, Jana
collection PubMed
description Myelodysplastic syndromes (MDS) are hematological malignancies of unclear etiology where oxidative stress may contribute to the pathogenesis. Methylarginines, naturally occurring inhibitors of NO synthase, can increase superoxide generation from uncoupled NO synthase. We found significant increase in concentrations of asymmetric dimethylarginine (0.84 ± 0.32 μmol/L, p = 0.0022) and malondialdehyde (0.77 ± 0.11 μmol/L, p < 0.001) in sera of MDS patients vs controls (asymmetric dimethylarginine: 0.56 ± 0.16 μmol/L, malondialdehyde: 0.52 ± 0.07 μmol/L). On the contrary, nitrites concentrations were significantly decreased in MDS patients (1.71 ± 0.46 μmol/L, p = 0.0028) vs controls (2.16 ± 0.38 μmol/L). We suppose that the oxidative stress in MDS is enhanced due to methylated arginines influence on NO synthase activity impairment.
format Online
Article
Text
id pubmed-3765587
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37655872013-09-08 Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome Štikarová, Jana Suttnar, Jiří Pimková, Kristýna Chrastinová-Mášová, Leona Čermák, Jaroslav Dyr, Jan E J Hematol Oncol Letter to the Editor Myelodysplastic syndromes (MDS) are hematological malignancies of unclear etiology where oxidative stress may contribute to the pathogenesis. Methylarginines, naturally occurring inhibitors of NO synthase, can increase superoxide generation from uncoupled NO synthase. We found significant increase in concentrations of asymmetric dimethylarginine (0.84 ± 0.32 μmol/L, p = 0.0022) and malondialdehyde (0.77 ± 0.11 μmol/L, p < 0.001) in sera of MDS patients vs controls (asymmetric dimethylarginine: 0.56 ± 0.16 μmol/L, malondialdehyde: 0.52 ± 0.07 μmol/L). On the contrary, nitrites concentrations were significantly decreased in MDS patients (1.71 ± 0.46 μmol/L, p = 0.0028) vs controls (2.16 ± 0.38 μmol/L). We suppose that the oxidative stress in MDS is enhanced due to methylated arginines influence on NO synthase activity impairment. BioMed Central 2013-08-19 /pmc/articles/PMC3765587/ /pubmed/23958336 http://dx.doi.org/10.1186/1756-8722-6-58 Text en Copyright © 2013 Štikarová et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Štikarová, Jana
Suttnar, Jiří
Pimková, Kristýna
Chrastinová-Mášová, Leona
Čermák, Jaroslav
Dyr, Jan E
Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
title Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
title_full Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
title_fullStr Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
title_full_unstemmed Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
title_short Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
title_sort enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765587/
https://www.ncbi.nlm.nih.gov/pubmed/23958336
http://dx.doi.org/10.1186/1756-8722-6-58
work_keys_str_mv AT stikarovajana enhancedlevelsofasymmetricdimethylarginineinaserumofmiddleagepatientswithmyelodysplasticsyndrome
AT suttnarjiri enhancedlevelsofasymmetricdimethylarginineinaserumofmiddleagepatientswithmyelodysplasticsyndrome
AT pimkovakristyna enhancedlevelsofasymmetricdimethylarginineinaserumofmiddleagepatientswithmyelodysplasticsyndrome
AT chrastinovamasovaleona enhancedlevelsofasymmetricdimethylarginineinaserumofmiddleagepatientswithmyelodysplasticsyndrome
AT cermakjaroslav enhancedlevelsofasymmetricdimethylarginineinaserumofmiddleagepatientswithmyelodysplasticsyndrome
AT dyrjane enhancedlevelsofasymmetricdimethylarginineinaserumofmiddleagepatientswithmyelodysplasticsyndrome